Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

PETRI DISH PERSPECTIVES

PETRI DISH PERSPECTIVES artwork

Episode 51: ImmunoGen

Apr 16, 202627 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Send us Fan Mail In this episode of Petri Dish Perspectives: Biotech Unleashed, we dive into the 40+ year journey of ImmunoGen, a company that refused to give up on one of the most complex and misunderstood technologies in oncology: antibody-drug conjugates (ADCs). From its early days as a Dana-Farber spinout to decades of scientific setbacks, market skepticism, and near-collapse moments, ImmunoGen’s story is anything but linear. We explore how the company survived the “ADC dark ages,” built foundational technology through partnerships with giants like Genentech and Roche, and ultimately made the bold pivot from platform provider to full-fledged drug developer. If you want to understand how long it really takes to build a platform technology, why being early can be both a curse and a competitive advantage, and how persistence shapes success in biotech, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #ImmunoGen #ADC #AntibodyDrugConjugates #Oncology #DrugDevelopment #Pharma #Biotechnology #CancerResearch #AbbVie #LifeSciences #BiotechPodcast #PetriDishPerspectives Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Episode 82: Dr. Natalie Ma on Building Virtual Humans to Predict Drug Safety

    Nov 19, 202655 minAudio

    Send us Fan Mail After earning a PhD in molecular biology at Yale, Dr. Natalie Ma moved from the bench to the business side of science to tackle drug development’s biggest problem: roughly 90% of programs fail, often...

    Credit the people on this episode

  2. Episode 81: Mithril Medicine (Now Anthropic)

    Nov 12, 202626 minAudio

    Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Mithril Medicine, the one-person biotech that Anthropic just acquired and the story behind the man who built it. Cody Tranbarger spent six years...

    Credit the people on this episode

  3. Episode 80: Dr. Meesha Dogan on Using AI and Epigenetics to Detect Heart Disease Early

    Nov 5, 202647 minAudio

    Send us Fan Mail After a two-generation family history of heart disease, Dr. Meesha Dogan set out to change how the disease is detected. As founder and CEO of Cardio Diagnostics, she built and commercialized what the...

    Credit the people on this episode

  4. October 2026: Biotech & Pharma NEWS Roundup

    Nov 1, 20269 minAudio

    Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for October 2026! This month was defined by a wave of oncology approvals, a head-to-head data drop that reshuffled...

    Credit the people on this episode

  5. Episode 79: Endeavor Health

    Oct 29, 202617 minAudio

    Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Endeavor Health, the Chicago-area hospital system most Illinoisans have driven past but couldn’t name. Born from Evanston Hospital in 1891, grown...

    Credit the people on this episode